Leerink Partnrs Issues Pessimistic Outlook for INSP Earnings

Key Points

• Leerink Partners has revised its FY2029 earnings per share estimate for Inspire Medical Systems, lowering it from $6.69 to $6.27, while the current consensus estimate for the company's full-year earnings is $2.16 per share.
• Multiple brokerages have issued mixed ratings on Inspire Medical Systems, with Robert W. Baird raising the price target to $236.00, while JPMorgan Chase downgraded the stock and cut its target price from $195.00 to $110.00.
• Inspire Medical Systems reported earnings of $0.45 per share for the recent quarter, exceeding the consensus estimate of $0.22, along with a revenue of $217.09 million, which surpassed analyst expectations of $214.50 million.

Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) - Analysts at Leerink Partnrs dropped their FY2029 earnings per share estimates for Inspire Medical Systems in a research note issued to investors on Tuesday, August 5th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of $6.27 per share for the year, down from their previous estimate of $6.69. The consensus estimate for Inspire Medical Systems' current full-year earnings is $2.16 per share.

Several other brokerages have also recently weighed in on INSP. Robert W. Baird upped their price target on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 6th. KeyCorp downgraded Inspire Medical Systems from an "overweight" rating to a "sector weight" rating in a report on Tuesday. Piper Sandler set a $150.00 target price on Inspire Medical Systems and gave the stock an "overweight" rating in a report on Tuesday. JPMorgan Chase & Co. downgraded Inspire Medical Systems from an "overweight" rating to a "neutral" rating and dropped their target price for the stock from $195.00 to $110.00 in a report on Tuesday. Finally, Stifel Nicolaus set a $140.00 target price on Inspire Medical Systems and gave the stock a "hold" rating in a report on Tuesday. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $173.31.

Inspire Medical Systems Stock Down 33.7%

Shares of INSP stock opened at $86.10 on Wednesday. The stock has a market cap of $2.54 billion, a price-to-earnings ratio of 49.77, a PEG ratio of 1.99 and a beta of 1.22. The business's fifty day moving average is $130.39 and its 200 day moving average is $153.83. Inspire Medical Systems has a twelve month low of $73.92 and a twelve month high of $225.00.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.39% and a net margin of 6.17%. The firm had revenue of $217.09 million for the quarter, compared to analysts' expectations of $214.50 million. During the same period in the previous year, the firm earned $0.32 earnings per share. The business's revenue was up 10.8% compared to the same quarter last year.

Institutional Trading of Inspire Medical Systems

Several institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC grew its holdings in Inspire Medical Systems by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 4,055 shares of the company's stock valued at $646,000 after buying an additional 521 shares in the last quarter. GAMMA Investing LLC grew its holdings in Inspire Medical Systems by 253.7% during the 1st quarter. GAMMA Investing LLC now owns 573 shares of the company's stock valued at $91,000 after buying an additional 411 shares in the last quarter. New York State Teachers Retirement System grew its holdings in Inspire Medical Systems by 132.7% during the 1st quarter. New York State Teachers Retirement System now owns 21,390 shares of the company's stock valued at $3,407,000 after buying an additional 12,196 shares in the last quarter. Bessemer Group Inc. grew its holdings in Inspire Medical Systems by 1.7% during the 1st quarter. Bessemer Group Inc. now owns 7,183 shares of the company's stock valued at $1,145,000 after buying an additional 123 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in Inspire Medical Systems by 356.5% during the 1st quarter. Parallel Advisors LLC now owns 210 shares of the company's stock valued at $33,000 after buying an additional 164 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.